SCHEMBL25345825

SCHEMBL25345825

C#CC[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.50
▸ THRB P10828 1/20 0.50
▸ MAPK1 P28482 2/20 0.48
▸ PYGB P11216 2/20 0.43
▸ CD69 Q07108 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25345827 1.00 ALDH1A1 (0.50) ALDH1A1THRBMAPK1PYGBCD69
SCHEMBL25976592 0.88 ALDH1A1 (0.41) ALDH1A1THRBMAPK1PYGBCD69
SCHEMBL17771655 0.86 ALDH1A1 (0.58) ALDH1A1THRBMAPK1PYGBCD69
SCHEMBL12936319 0.86 ALDH1A1 (0.58) ALDH1A1THRBMAPK1PYGBCD69
SCHEMBL18735615 0.81 ALDH1A1 (0.58) ALDH1A1THRBMAPK1PYGBCD69
SCHEMBL20842452 0.81 ALDH1A1 (0.58) ALDH1A1THRBMAPK1PYGBCD69
SCHEMBL18573708 0.81 ALDH1A1 (0.58) ALDH1A1THRBMAPK1PYGBCD69
SCHEMBL22431361 0.81 ALDH1A1 (0.58) ALDH1A1THRBMAPK1PYGBCD69
SCHEMBL16393013 0.81 ALDH1A1 (0.55) ALDH1A1THRBMAPK1PYGBCD69
SCHEMBL30980513 0.81 ALDH1A1 (0.51) ALDH1A1THRBMAPK1PYGBCD69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
US-20250101007-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. 2025-03-27 — — US disclosed
US-12258332-B2 ASGPR cell surface receptor binding compounds and conjugates LYCIA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
EP-4370157-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2024-05-22 — — EP disclosed
US-20230250091-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. 2023-08-10 — — US disclosed
US-20230250091-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. 2023-08-10 — — US disclosed
WO-2023288033-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2023-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258332-B2 ASGPR cell surface receptor binding compounds and conjugates ASGR1, LAMP2, FCGR2A ALDH1A1 2955/4885THRB 1561/4885MAPK1 2970/4885
US-20250101007-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES ASGR1, LAMP2, FCGR2A ALDH1A1 2955/4885THRB 1561/4885MAPK1 2970/4885
US-20230250091-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES ASGR1, LAMP2, FCGR2A ALDH1A1 2955/4885THRB 1561/4885MAPK1 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback